AIDS landmark trials: Difference between revisions
Jump to navigation
Jump to search
No edit summary |
|||
| Line 1: | Line 1: | ||
{{AIDS}} | {{AIDS}} | ||
{{CMG}} [[User:Ujjwal Rastogi|Ujjwal Rastogi, MBBS]] [mailto:urastogi@perfuse.org] | {{CMG}} [[User:Ujjwal Rastogi|Ujjwal Rastogi, MBBS]] [mailto:urastogi@perfuse.org] | ||
==Overview== | |||
Clinical trials are a set of procedures in medical research and drug development that are conducted to allow safety (or more specifically, information about adverse drug reactions and adverse effects of other treatments) and efficacy data to be collected for health interventions (e.g., drugs, diagnostics, devices, therapy protocols). Several trials have been conducted till date that have immense contribution. | |||
=== Clinical trials of Non-nucleoside reverse transcriptase inhibitors === | === Clinical trials of Non-nucleoside reverse transcriptase inhibitors === | ||
'''1. Efavirenz and nevirapine (2NN study)''' (2004)<ref name="pmid15094269">{{cite journal |author=van Leth F, Phanuphak P, Ruxrungtham K, Baraldi E, Miller S, Gazzard B, Cahn P, Lalloo UG, van der Westhuizen IP, Malan DR, Johnson MA, Santos BR, Mulcahy F, Wood R, Levi GC, Reboredo G, Squires K, Cassetti I, Petit D, Raffi F, Katlama C, Murphy RL, Horban A, Dam JP, Hassink E, van Leeuwen R, Robinson P, Wit FW, Lange JM |title=Comparison of first-line antiretroviral therapy with regimens including nevirapine, efavirenz, or both drugs, plus stavudine and lamivudine: a randomised open-label trial, the 2NN Study |journal=Lancet |volume=363 |issue=9417 |pages=1253–63 |year=2004 |month=April |pmid=15094269 |doi=10.1016/S0140-6736(04)15997-7 |url=http://linkinghub.elsevier.com/retrieve/pii/S0140673604159977 |accessdate=2012-02-21}}</ref> | '''1. Efavirenz and nevirapine (2NN study)''' (2004)<ref name="pmid15094269">{{cite journal |author=van Leth F, Phanuphak P, Ruxrungtham K, Baraldi E, Miller S, Gazzard B, Cahn P, Lalloo UG, van der Westhuizen IP, Malan DR, Johnson MA, Santos BR, Mulcahy F, Wood R, Levi GC, Reboredo G, Squires K, Cassetti I, Petit D, Raffi F, Katlama C, Murphy RL, Horban A, Dam JP, Hassink E, van Leeuwen R, Robinson P, Wit FW, Lange JM |title=Comparison of first-line antiretroviral therapy with regimens including nevirapine, efavirenz, or both drugs, plus stavudine and lamivudine: a randomised open-label trial, the 2NN Study |journal=Lancet |volume=363 |issue=9417 |pages=1253–63 |year=2004 |month=April |pmid=15094269 |doi=10.1016/S0140-6736(04)15997-7 |url=http://linkinghub.elsevier.com/retrieve/pii/S0140673604159977 |accessdate=2012-02-21}}</ref> | ||
Revision as of 23:08, 21 February 2012
|
AIDS Microchapters |
|
Diagnosis |
|
Treatment |
|
Case Studies |
|
AIDS landmark trials On the Web |
|
American Roentgen Ray Society Images of AIDS landmark trials |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1] Ujjwal Rastogi, MBBS [2]
Overview
Clinical trials are a set of procedures in medical research and drug development that are conducted to allow safety (or more specifically, information about adverse drug reactions and adverse effects of other treatments) and efficacy data to be collected for health interventions (e.g., drugs, diagnostics, devices, therapy protocols). Several trials have been conducted till date that have immense contribution.
Clinical trials of Non-nucleoside reverse transcriptase inhibitors
1. Efavirenz and nevirapine (2NN study) (2004)[1]
- Purpose : It was a randomised comparison of the non-nucleoside reverse-transcriptase inhibitors (NNRTI) nevirapine and efavirenz.
- Study Design: Randomised trial
References
- ↑ van Leth F, Phanuphak P, Ruxrungtham K, Baraldi E, Miller S, Gazzard B, Cahn P, Lalloo UG, van der Westhuizen IP, Malan DR, Johnson MA, Santos BR, Mulcahy F, Wood R, Levi GC, Reboredo G, Squires K, Cassetti I, Petit D, Raffi F, Katlama C, Murphy RL, Horban A, Dam JP, Hassink E, van Leeuwen R, Robinson P, Wit FW, Lange JM (2004). "Comparison of first-line antiretroviral therapy with regimens including nevirapine, efavirenz, or both drugs, plus stavudine and lamivudine: a randomised open-label trial, the 2NN Study". Lancet. 363 (9417): 1253–63. doi:10.1016/S0140-6736(04)15997-7. PMID 15094269. Retrieved 2012-02-21. Unknown parameter
|month=ignored (help)